Specialty Pharmacy

Researchers target effect of various medical conditions on platelet function.

New treatment option for patients who no longer respond to Xalkori.

Enhanced screening and treatment in high-risk populations could eliminate virus.

Top stories of the week on Specialty Pharmacy Times.

Researchers target how cancer cells avoid treatment.

Clean needle programs have reduced HIV incidence among injection drug abusers by 80% from 1990 to 2006.

Shopping around carefully for plans will be important for Medicare Part D enrollees.

Through a voluntary field safety notification, Insulet Corporation is notifying consumers and health care professionals about a slight increase in reports in which the OmniPod's needle mechanism to deliver insulin fails to deploy or is delayed.

Asthma may increase the likelihood of chronic migraines in patients with episodic migraines.

CMS report shows spending rates are lower compared with the years prior to health care reform.

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

MS patients with visual problems perform worse in testing than patients without visual problems but with MS.

Higher number of unprotected sexual encounters correlates with enhanced cell expressions.

Early treatment found to be cost-effective compared with waiting until liver fibrosis worsens.

Overall survival rate nearly doubles in patients who used aspirin post-diagnosis.

Addition of midostaurin to chemotherapy shows promise in patients with AML.

Successful response to hepatitis C treatment shows a 30 percent increased reduction in liver stiffness.

Majority of hemophilia patients show problems with mobility, daily activities, and pain.

Normal growth in lung function in early adulthood an important factor in terms of future COPD risk.

Experts provide unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma.

Rare disease can cause serious liver and cardiovascular conditions.

Addition of bortezomib to lenalidomide and low-dose dexamethasone therapy extends disease control.

Researchers determine how the liver is able to naturally inhibit HCV infection.

Scientists discover threat from AAV2 virus and from correlation to the development of liver cancer.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Anemia caused by chemotherapy for lymphoid malignancies improved in patients with non-Hodgkin's lymphoma and multiple myeloma.

Warnings about the risk of ketoacidosis and serious urinary tract infections have been added to the labels of SGLT2 inhibitors.

Potentially game changing drug may alter diabetes disease course.

David Lassen, chief clinical officer at Prime Therapeutics, discusses implications for specialty pharmacy from health care reform.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.